NasdaqGM:NTLABiotechs
Will Narrowing Six‑Month Losses Shape Intellia Therapeutics' (NTLA) Gene‑Editing Investment Narrative?
In the second quarter of 2026, Intellia Therapeutics reported a net loss of US$106.63 million, with basic loss per share from continuing operations of US$0.80, while its six‑month net loss reached US$202.87 million and basic loss per share was US$1.61, both reflecting reduced losses versus a year earlier.
The combination of a slightly higher quarterly net loss but improved loss per share, alongside a smaller half‑year net loss, may influence how investors assess Intellia’s progress in...